MX2010009157A - Suministro mejorado de un agente terapeutico para tejidos oculares a traves de iontoforesis. - Google Patents

Suministro mejorado de un agente terapeutico para tejidos oculares a traves de iontoforesis.

Info

Publication number
MX2010009157A
MX2010009157A MX2010009157A MX2010009157A MX2010009157A MX 2010009157 A MX2010009157 A MX 2010009157A MX 2010009157 A MX2010009157 A MX 2010009157A MX 2010009157 A MX2010009157 A MX 2010009157A MX 2010009157 A MX2010009157 A MX 2010009157A
Authority
MX
Mexico
Prior art keywords
iontophoresis
therapeutic
enhanced delivery
ocular tissues
delivery
Prior art date
Application number
MX2010009157A
Other languages
English (en)
Inventor
Mike Patane
Mike Jaffe
Gary Cook
Perry Calias
Original Assignee
Eyegate Pharma S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyegate Pharma S A S filed Critical Eyegate Pharma S A S
Publication of MX2010009157A publication Critical patent/MX2010009157A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008Introducing ophthalmic products into the ocular cavity or retaining products therein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0408Use-related aspects
    • A61N1/0428Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448Drug reservoir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/20Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303Constructional details
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0408Use-related aspects
    • A61N1/0428Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432Anode and cathode
    • A61N1/044Shape of the electrode

Abstract

Se describen en la presente formulaciones de dexametasona o uno de sus profármacos adecuados para suministro a través de iontoforesis ocular y sus métodos de uso.
MX2010009157A 2008-02-25 2009-02-24 Suministro mejorado de un agente terapeutico para tejidos oculares a traves de iontoforesis. MX2010009157A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3126708P 2008-02-25 2008-02-25
US4795008P 2008-04-25 2008-04-25
PCT/US2009/034977 WO2009108626A2 (en) 2008-02-25 2009-02-24 Enhanced delivery of a therapeutic to ocular tissues through iontophoresis

Publications (1)

Publication Number Publication Date
MX2010009157A true MX2010009157A (es) 2010-09-24

Family

ID=41016683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009157A MX2010009157A (es) 2008-02-25 2009-02-24 Suministro mejorado de un agente terapeutico para tejidos oculares a traves de iontoforesis.

Country Status (10)

Country Link
US (4) US20090306579A1 (es)
EP (1) EP2249921B1 (es)
JP (1) JP2011512903A (es)
CN (1) CN101970042A (es)
AU (1) AU2009219426B2 (es)
BR (1) BRPI0908229A8 (es)
CA (1) CA2716390C (es)
IL (1) IL207014A0 (es)
MX (1) MX2010009157A (es)
WO (1) WO2009108626A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970042A (zh) 2008-02-25 2011-02-09 眼门药品公司 经由离子电渗法增强递送治疗药物至眼部组织
EP2370155B1 (en) * 2008-12-31 2018-07-04 Eyegate Pharmaceuticals, Inc. System for ocular iontophoresis with buffering
US20130310732A1 (en) * 2011-01-12 2013-11-21 Sooft Italia Spa Corneal delivery of cross-linking agents by iontophoresis for the treatment of keratoconus and related ophthalmic compositions
WO2012162459A1 (en) * 2011-05-26 2012-11-29 Pepose Jay Device and method for administering eye medications
JP5463511B1 (ja) * 2013-05-13 2014-04-09 株式会社メディカル・アート イオン泳動式皮膚感染症治療装置
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CN106413642B (zh) * 2014-04-23 2019-03-08 塞罗斯医学有限责任公司 真空辅助药物递送装置
CN106794152A (zh) * 2014-08-13 2017-05-31 约翰霍普金斯大学 用于预防角膜同种异体移植物排斥和新生血管形成的载有糖皮质激素的纳米颗粒
WO2016100972A2 (en) * 2014-12-19 2016-06-23 Kemin Industries, Inc. Intraocular delivery of bioactive molecules using iontophoresis
WO2016118933A1 (en) 2015-01-22 2016-07-28 Eyegate Pharmaceuticals, Inc. Iontophoretic contact lens
KR102450674B1 (ko) 2015-03-05 2022-10-04 오클랜드 유니서비시즈 리미티드 안과용 조성물 및 이의 사용 방법
WO2019089537A1 (en) 2017-10-31 2019-05-09 Tusker Medical, Inc. Systems, apparatus, and methods for delivery of therapeutic substance to nasal cavity
CN113660934A (zh) 2018-11-21 2021-11-16 特默罗制药股份有限公司 罗非昔布的纯化形式、制备方法和用途
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4279900A (en) * 1978-07-13 1981-07-21 Intrex Research Corporation Prodrugs for the improved delivery of halogen-containing glucocorticosteroids
US4456602A (en) * 1982-08-23 1984-06-26 The Upjohn Company Amine containing ester prodrugs of corticosteroids
US4443440A (en) * 1982-08-30 1984-04-17 The Upjohn Company Amine containing ester prodrugs of corticosteroids
US4472392A (en) * 1983-01-21 1984-09-18 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
US4469689A (en) * 1983-03-30 1984-09-04 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
US4588718A (en) * 1984-03-28 1986-05-13 The Upjohn Company Carboxy containing ester prodrugs of corticosteroids
GB9024005D0 (en) * 1990-11-05 1990-12-19 British Bio Technology Process for amplifying nucleic acid
US5222936A (en) * 1991-09-25 1993-06-29 Stephen Robert L Intracorporeal iontophoretic method
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
ATE195127T1 (de) * 1993-09-29 2000-08-15 Nissin Food Products Ltd In stellung 21 substituierte steroide
US6650934B2 (en) * 1996-12-17 2003-11-18 Alza Corp Polymeric foam reservoirs for an electrotransport delivery device
US6050934A (en) * 1997-02-26 2000-04-18 Cv Dynamics, Inc. Urinary catheter having palpitatable discharge valve with protective shoulders
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
CN1063944C (zh) * 1997-04-14 2001-04-04 齐鲁制药厂 眼用复方妥布霉素混悬液的制法
FR2773320B1 (fr) * 1998-01-05 2000-03-03 Optisinvest Dispositif pour le transfert intraoculaire de produits actifs par iontophorese
JP2000316991A (ja) * 1999-05-13 2000-11-21 Hisamitsu Pharmaceut Co Inc イオントフォレーシス装置の電極構造体及びその製造方法
JP4414517B2 (ja) 1999-09-01 2010-02-10 久光製薬株式会社 イオントフォレーシス用デバイス構造体
AU776609B2 (en) 1999-09-24 2004-09-16 Novartis Ag Topical suspension formulations containing ciprofloxacin and dexamethasone
US6395756B2 (en) * 1999-12-23 2002-05-28 Novartis Ag Use of ophthalmic agent
US6697668B2 (en) 2001-01-25 2004-02-24 Iomed, Inc. Ocular iontophoretic device and method for using the same
US20030023228A1 (en) * 2001-07-20 2003-01-30 Parkinson Thomas M. Ocular iontophoretic device and method for using the same
EP1596823A2 (en) 2003-02-21 2005-11-23 Sun Pharmaceuticals Industries Ltd. A stable ophthalmic composition
JP3493359B1 (ja) * 2003-03-20 2004-02-03 宣美 辛島 イオン泳動式治療装置
FR2855761B1 (fr) * 2003-06-03 2006-02-24 Optis France Sa Dispositif oculaire de delivrance variable de principes actifs par iontophorese
JP4820647B2 (ja) * 2003-08-29 2011-11-24 久光製薬株式会社 イオントフォレーシス投与組成物
CA2562356A1 (en) * 2004-04-08 2005-10-27 Retmed Pty Ltd Treatment of ophthalmic conditions with mineralcorticoids
FR2869531B1 (fr) * 2004-04-30 2006-07-14 Optis France Sa Sa Dispositif de iontophorese oculaire diminuant les irritations
US20060110428A1 (en) 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
WO2006072887A1 (en) 2005-01-05 2006-07-13 Eyegate Pharma Sa Ocular iontophoresis device for delivering sirna and aptamers
US8386030B2 (en) * 2005-08-08 2013-02-26 Tti Ellebeau, Inc. Iontophoresis device
US8099162B2 (en) * 2005-11-29 2012-01-17 Eyegate Pharma, S.A.S. Ocular iontophoresis device
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US8048448B2 (en) * 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US20080027371A1 (en) * 2006-07-26 2008-01-31 Higuchi John W Method and device for minimally invasive site specific ocular drug delivery
WO2008057360A1 (en) * 2006-11-02 2008-05-15 Riolan Technologies, Inc. Methods of treating an ocular allergy with low dose dexamethasone
CN101970042A (zh) 2008-02-25 2011-02-09 眼门药品公司 经由离子电渗法增强递送治疗药物至眼部组织
US8030297B2 (en) * 2008-05-14 2011-10-04 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders

Also Published As

Publication number Publication date
US20140046242A1 (en) 2014-02-13
CN101970042A (zh) 2011-02-09
US10376463B2 (en) 2019-08-13
IL207014A0 (en) 2010-12-30
BRPI0908229A2 (pt) 2017-06-13
WO2009108626A2 (en) 2009-09-03
JP2011512903A (ja) 2011-04-28
BRPI0908229A8 (pt) 2017-10-10
WO2009108626A3 (en) 2010-01-07
US20160263024A1 (en) 2016-09-15
CA2716390C (en) 2016-08-23
US9820935B2 (en) 2017-11-21
US20120283231A1 (en) 2012-11-08
US9149525B2 (en) 2015-10-06
EP2249921B1 (en) 2020-06-17
EP2249921A4 (en) 2015-02-11
EP2249921A2 (en) 2010-11-17
AU2009219426A1 (en) 2009-09-03
US20090306579A1 (en) 2009-12-10
CA2716390A1 (en) 2009-09-03
AU2009219426B2 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
MX2010009157A (es) Suministro mejorado de un agente terapeutico para tejidos oculares a traves de iontoforesis.
WO2009023311A9 (en) Transcutaneous delivery of therapeutic agents
CA2711696C (en) Therapeutic compositions for treatment of ocular inflammatory disorders
SG10201510586PA (en) Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
MX370543B (es) Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
EP2493475A4 (en) COSMETIC METHODS AND PREPARATIONS FOR THE PROLONGED RELEASE OF THERAPEUTIC AGENTS IN THE EYE
ZA201400616B (en) Methods and devices for drug delivery to ocular tissue using microneedle
EP2187743A4 (en) FORMULATIONS FOR THE TREATMENT OF DISEASES OR EYE DISORDERS
MX369616B (es) Composiciones cutaneas y metodos para su uso.
MX357801B (es) Agentes dirigidos a gadd45beta.
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
MY173215A (en) Acetylcysteine compositions and methods of use thereof
MX2010002736A (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de tinnitus coclear.
ZA201200017B (en) Formulations for the treatment of deeep tissue pain
WO2009114703A3 (en) Combination therapy for the treatment of cancer
EA201190337A1 (ru) Способ лечения
AU324215S (en) Handpiece for massage or therapy
EP2306824A4 (en) IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER
WO2012040636A3 (en) Compounds and methods for treating diseases mediated by protease activated receptors
WO2011044523A3 (en) Compositions and methods for treating obesity
WO2009132234A3 (en) Medical devices, polymers, compositions, and methods for delivering a haloacetate
IL198202A0 (en) Peptide-cytotoxic conjugates
MX2010006019A (es) Metodos para administrar acido ribonucleico pequeño de interferencia (arnsi) mediante iontoforesis.
UA112981C2 (uk) Варіант людського gdnf

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: EYEGATE PHARMACEUTICALS, INC.

FG Grant or registration